. "Sta\u0148kov\u00E1, Barbora" . . . "Fatty acids in patients with pancreatic carcinoma and other malignancies"@en . . "Praha" . "5"^^ . . "I" . "Praha" . "Pancreatic carcinoma (PC) is very serious oncologic disease with the very bad prognosis. Severe malnutrition and deregulation of fatty acids (FA) metabolism are connected with PC. Abnormal metabolism of FA is also present in other oncologic diseases, in cardiovascular diseases, in obesity and in diabetes mellitus type 2. Dietary intake of FA over several weeks as well as endogenic metabolism (synthesis, lipoperoxidation) of FA both influence the composition of FA in plasma phospholipids and cholesteryl esters. Several studies proved the association of risk for malignancies including PC with total fat and saturated FA intake. Risk for PC was lower in obese patients who consumed increased amount of polyunsaturated FA and decreased amount of saturated FA. High intake of n-6 polyunsaturated FA, especially linoleic acid, increases the risk for development of gastrointestinal tumours such as colorectal carcinoma, PC and also breast and prostate carcinoma. Epidemiological studies proved beneficial effects of n-3 polyunsaturated FA in the risk and progession of tumours. Generally, n-6 polyunsaturated FA acts as enhancing factor for proliferation and invasiveness of tumours, metastases formation and inflammatory reaction of the organism, whereas n-3 polyunsaturated FA opposes these effects. Increased de novo synthesis of FA due to overexpression of FA synthase (FAS) and stearoyl-CoA desaturase (SCD-1) is present in malignant tumours. Physiologically, FAS is expressed only in the fat tissue and in the liver. Pathologically, FAS is expressed in tumour cells to satisfy nutritional requirements of these cells."@en . "Fatty acids in patients with pancreatic carcinoma and other malignancies"@en . . . . . "Tvrzick\u00E1, Eva" . . "2012-09-12+02:00"^^ . . "RIV/00064165:_____/12:12936" . "Mac\u00E1\u0161ek, Jaroslav" . "6"^^ . "Mastn\u00E9 kyseliny u karcinomu pankreatu a jin\u00FDch onkologick\u00FDch onemocn\u011Bn\u00ED" . . "Vecka, Marek" . "RIV/00064165:_____/12:12936!RIV13-MZ0-00064165" . . "978-80-260-2984-7" . . . . . "Mastn\u00E9 kyseliny u karcinomu pankreatu a jin\u00FDch onkologick\u00FDch onemocn\u011Bn\u00ED" . . "Fatty acids; pancreatic cancer; oncologic diseases; diabetes mellitus; obesity; cardiovascular diseases; malignant tumours"@en . "Mastn\u00E9 kyseliny u karcinomu pankreatu a jin\u00FDch onkologick\u00FDch onemocn\u011Bn\u00ED"@cs . "148596" . . "4"^^ . "\u017D\u00E1k, Ale\u0161" . "\u010Cesk\u00E1 l\u00E9ka\u0159sk\u00E1 spole\u010Dnost J.E. Purkyn\u011B a IV. intern\u00ED klinika 1. LF UK a VFN" . . "Mastn\u00E9 kyseliny u karcinomu pankreatu a jin\u00FDch onkologick\u00FDch onemocn\u011Bn\u00ED"@cs . "Karcinom pankreatu (KP) je velmi z\u00E1va\u017En\u00E9 onkologick\u00E9 onemocn\u011Bn\u00ED se \u0161patnou progn\u00F3zou. KP je doprov\u00E1zen z\u00E1va\u017Enou malnutric\u00ED se zm\u011Bn\u011Bn\u00FDm metabolismem mastn\u00FDch kyselin (MK). Zm\u011Bna metabolismu MK je nach\u00E1zena i u jin\u00FDch onkologick\u00FDch onemocn\u011Bnh, d\u00E1le u kardiovaskul\u00E1rn\u00EDch chorob, p\u0159i obezit\u011B \u010Di diabetes mellitus 2. Typu. Slo\u017Een\u00ED mastn\u00FDch kyselin v plasmatick\u00FDch fosfolipidech a cholesterylesterech odpov\u00EDd\u00E1 jednak exogenn\u00EDmu p\u0159\u00EDjmu mastn\u00FDch kyselin v pr\u016Fb\u011Bhu n\u011Bkolika t\u00FDdn\u016F jako\u017Eto i endogenn\u00EDmu metabolizmu MK (synt\u00E9za, lipoperoxidace atd.). V n\u011Bkolika studi\u00EDch bylo prok\u00E1z\u00E1no, \u017Ee p\u0159\u00EDjem tuku a nasycen\u00FDch mastn\u00FDch kyselin je asociov\u00E1n s rizikem vzniku onkologick\u00FDch onemocn\u011Bn\u00ED v\u010Detn\u011B karcinomu pankreatu. U ob\u00E9zn\u00EDch jedinc\u016F do\u0161lo ke sn\u00ED\u017Een\u00ED rizika vzniku karcinomu pankreatu p\u0159i zv\u00FD\u0161en\u00E9m p\u0159\u00EDjmu v\u00EDcenenasycen\u00FDch mastn\u00FDch kyselin na \u00FAkor t\u011Bch nasycen\u00FDch. Vysok\u00FD p\u0159\u00EDjem vicenenasycen\u00FDch mastn\u00FDch kyselin \u0159ady n-6 , zvl\u00E1\u0161t\u011B kyseliny linolov\u00E9, zvy\u0161uje riziko vzniku n\u00E1doru tr\u00E1vic\u00EDho traktu (kolorekt\u00E1ln\u00ED karcinom, karcinom pankreatu), karcinomu prsu a prostaty. Zat\u00EDmco v\u00EDcenenasycen\u00E9 mastn\u00E9 kyseliny \u0159ady n-3 p\u016Fsob\u00ED proti vzniku n\u00E1dorov\u00FDch onemocn\u011Bni. Obecn\u011B lze \u0159\u00EDci, \u017Ee v\u00EDcenenasycen\u00E9 mastn\u00E9 kyseliny \u0159ady n-6 podporuj\u00ED proliferaci tumoru, invazivitu, metastazov\u00E1n\u00ED a obecn\u011B reakci organizmu (z\u00E1n\u011Btlivou, imunitn\u00ED atd.), kde\u017Eto v\u00EDcenenasycen\u00E9 mastn\u00E9 kyseliny \u0159ady n-3 p\u016Fsob\u00ED opa\u010Dn\u011B. U n\u011Bkter\u00FDch druh\u016F n\u00E1dor\u016F je zv\u00FD\u0161ena de novo synt\u00E9za MK na podklad\u011B zv\u00FD\u0161en\u00E9 exprese synt\u00E1zy MK a stearoyi-CoA desatur\u00E1zy (SCD-1). Synt\u00E1za MK je enzym, kter\u00FD je fyziologicky exprimov\u00E1n pouze v tukov\u00E9 tk\u00E1ni a j\u00E1trech. V rakovinn\u00FDch bu\u0148k\u00E1ch je exprimov\u00E1n za \u00FA\u010Delem uspokojen\u00ED nutri\u010Dn\u00EDch pot\u0159eb t\u011Bchto bun\u011Bk." . "Zeman, Miroslav" . "Atherosklerosa" . . . . "[3C4433B921D6]" . "Karcinom pankreatu (KP) je velmi z\u00E1va\u017En\u00E9 onkologick\u00E9 onemocn\u011Bn\u00ED se \u0161patnou progn\u00F3zou. KP je doprov\u00E1zen z\u00E1va\u017Enou malnutric\u00ED se zm\u011Bn\u011Bn\u00FDm metabolismem mastn\u00FDch kyselin (MK). Zm\u011Bna metabolismu MK je nach\u00E1zena i u jin\u00FDch onkologick\u00FDch onemocn\u011Bnh, d\u00E1le u kardiovaskul\u00E1rn\u00EDch chorob, p\u0159i obezit\u011B \u010Di diabetes mellitus 2. Typu. Slo\u017Een\u00ED mastn\u00FDch kyselin v plasmatick\u00FDch fosfolipidech a cholesterylesterech odpov\u00EDd\u00E1 jednak exogenn\u00EDmu p\u0159\u00EDjmu mastn\u00FDch kyselin v pr\u016Fb\u011Bhu n\u011Bkolika t\u00FDdn\u016F jako\u017Eto i endogenn\u00EDmu metabolizmu MK (synt\u00E9za, lipoperoxidace atd.). V n\u011Bkolika studi\u00EDch bylo prok\u00E1z\u00E1no, \u017Ee p\u0159\u00EDjem tuku a nasycen\u00FDch mastn\u00FDch kyselin je asociov\u00E1n s rizikem vzniku onkologick\u00FDch onemocn\u011Bn\u00ED v\u010Detn\u011B karcinomu pankreatu. U ob\u00E9zn\u00EDch jedinc\u016F do\u0161lo ke sn\u00ED\u017Een\u00ED rizika vzniku karcinomu pankreatu p\u0159i zv\u00FD\u0161en\u00E9m p\u0159\u00EDjmu v\u00EDcenenasycen\u00FDch mastn\u00FDch kyselin na \u00FAkor t\u011Bch nasycen\u00FDch. Vysok\u00FD p\u0159\u00EDjem vicenenasycen\u00FDch mastn\u00FDch kyselin \u0159ady n-6 , zvl\u00E1\u0161t\u011B kyseliny linolov\u00E9, zvy\u0161uje riziko vzniku n\u00E1doru tr\u00E1vic\u00EDho traktu (kolorekt\u00E1ln\u00ED karcinom, karcinom pankreatu), karcinomu prsu a prostaty. Zat\u00EDmco v\u00EDcenenasycen\u00E9 mastn\u00E9 kyseliny \u0159ady n-3 p\u016Fsob\u00ED proti vzniku n\u00E1dorov\u00FDch onemocn\u011Bni. Obecn\u011B lze \u0159\u00EDci, \u017Ee v\u00EDcenenasycen\u00E9 mastn\u00E9 kyseliny \u0159ady n-6 podporuj\u00ED proliferaci tumoru, invazivitu, metastazov\u00E1n\u00ED a obecn\u011B reakci organizmu (z\u00E1n\u011Btlivou, imunitn\u00ED atd.), kde\u017Eto v\u00EDcenenasycen\u00E9 mastn\u00E9 kyseliny \u0159ady n-3 p\u016Fsob\u00ED opa\u010Dn\u011B. U n\u011Bkter\u00FDch druh\u016F n\u00E1dor\u016F je zv\u00FD\u0161ena de novo synt\u00E9za MK na podklad\u011B zv\u00FD\u0161en\u00E9 exprese synt\u00E1zy MK a stearoyi-CoA desatur\u00E1zy (SCD-1). Synt\u00E1za MK je enzym, kter\u00FD je fyziologicky exprimov\u00E1n pouze v tukov\u00E9 tk\u00E1ni a j\u00E1trech. V rakovinn\u00FDch bu\u0148k\u00E1ch je exprimov\u00E1n za \u00FA\u010Delem uspokojen\u00ED nutri\u010Dn\u00EDch pot\u0159eb t\u011Bchto bun\u011Bk."@cs .